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Abstract
The von Hippel-Lindau (VHL) syndrome is a pleomorphic familial disease characterized by the development of highly
vascularized tumors, such as hemangioblastomas of the central nervous system, pheochromocytomas, renal cell
carcinomas, cysts and neuroendocrine tumors of the pancreas. Up to 75% of VHL patients are affected by VHL-associated
pancreatic lesions; however, very few reports in the published literature have described the cellular origins and biological
roles of VHL in the pancreas. Since homozygous loss of Vhl in mice resulted in embryonic lethality, this study aimed to
characterize the functional significance of VHL in the pancreas by conditionally inactivating Vhl utilizing the Cre/LoxP
system. Specifically, Vhl was inactivated in different pancreatic cell populations distinguished by their roles during
embryonic organ development and their endocrine lineage commitment. With Cre recombinase expression directed by a
glucagon promoter in a-cells or an insulin promoter in b-cells, we showed that deletion of Vhl is dispensable for normal
functions of the endocrine pancreas. In addition, deficiency of VHL protein (pVHL) in terminally differentiated a-cells or b-
cells is insufficient to induce pancreatic neuroendocrine tumorigenesis. Most significantly, we presented the first mouse
model of VHL-associated pancreatic disease in mice lacking pVHL utilizing Pdx1-Cre transgenic mice to inactivate Vhl in
pancreatic progenitor cells. The highly vascularized microcystic adenomas and hyperplastic islets that developed in Pdx1-
Cre;Vhl f/f homozygous mice exhibited clinical features similar to VHL patients. Establishment of three different, cell-specific
Vhl knockouts in the pancreas have allowed us to provide evidence suggesting that VHL is functionally important for
postnatal ductal and exocrine pancreas, and that VHL-associated pancreatic lesions are likely to originate from progenitor
cells, not mature endocrine cells. The novel model systems reported here will provide the basis for further functional and
genetic studies to define molecular mechanisms involved in VHL-associated pancreatic diseases.
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Introduction
The von Hippel-Lindau (VHL) syndrome is an autosomal,
dominant inherited disorder caused by mutations in the VHL
tumor suppressor gene. VHL patients are predisposed to develop
highly vascular tumors in multiple organs, including hemangio-
blastomas of the retina and central nervous system (CNS), clear
cell renal carcinomas, pheochromocytomas, cyst and neuroendo-
crine tumors in the pancreas [1]. This familial cancer syndrome is
caused by germ-line mutations in the VHL gene, which was
mapped to chromosome 3p25 by positional cloning [2]. Following
Knudson’s two-hit hypothesis, loss or inactivation of the remaining
wildtype allele is associated with VHL tumorigenesis [3,4]. The
spectrum of VHL tumors in affected families varies [5] and
biochemical analysis of the VHL gene product has provided the
molecular basis that explains the phenotype-genotype correlations
evident in VHL disease [6,7,8,9].
At the molecular level, the von Hippel-Lindau protein (pVHL)
is a critical factor in the oxygen sensing pathway. Under normoxic
conditions, pVHL forms a multiprotein complex with E3 ubiquitin
ligase that targets the a-subunits of hypoxia-inducible factor
(HIFa) for degradation by the proteosome [10,11]. Under hypoxic
conditions, HIFa subunits escape ubiquitin-mediated proteolysis,
allowing HIFa to accumulate, translocate to the nucleus, and
activate downstream targets. In subsets of VHL mutations, the
lack of functional pVHL leads to accumulation of HIF, and results
in the activation of HIFa target genes even in the presence of
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e4897oxygen [12]. Enhanced transcription of a wide variety of HIFa
target genes, such as vascular endothelial growth factor (VEGF), is
thought to contribute to the highly vascular tumors that develop in
VHL patients [13]. Independent of its function in regulating the
HIFa pathway, pVHL also binds other cellular proteins [14,15,16]
and promotes extracellular matrix assembly [16,17]. For example,
pVHL has been shown to bind and stabilize microtubule
structures [18], and regulate fibronectin deposition to maintain
vascular integrity [19,20].
Expression of VHL has been reported in most tissues and cell
types, but little is known about its role in normal development
[2,21,22]. Homozygous inactivation of Vhl in mice resulted in
embryonic lethality at embryonic stage (E) E10.5–E12.5 due to
defects in placental vasculogenesis [23]. Thus, tissue-specific
knockout of Vhl has been utilized to investigate the biological
functions of pVHL. Inactivation of Vhl utilizing an albumin-cre in
liver or a mosaic b-actin-cre resulted in hepatic vascular tumors
[24,25], similar to the ones observed in Vhl heterozygous knockout
animals. Unexpected roles of Vhl in spermatogenesis, thymus cell
survival, and bone development have also been reported with
conditional loss of pVHL [25,26,27]. Notably, inactivation of Vhl
in renal epithelial cells led to development of tubular cysts that
share morphologic and molecular characteristics with renal cysts
found in VHL patients [28]. While genetic analysis of Vhl in mice
have uncovered novel functions of pVHL in various tissues, much
is yet to be learned about pVHL’s role in organs normally affected
in VHL patients, such as CNS, adrenals and pancreas.
In VHL patients, the most common manifestations affecting the
pancreas are benign cysts and microcystic adenomas (MCA),
which occur in 35–75% of VHL patients [29,30]. In addition, 12–
17% of VHL patients develop pancreatic neuroendocrine (islet
cell) tumors, which possess the malignant potential to develop
metastasis [31,32]. However, the cellular origins and molecular
mechanisms leading to these pancreatic lesions found in VHL
patients are not known. Here we present three mouse models of
VHL in the pancreas generated by conditionally inactivating Vhl
in specific pancreatic cell populations. Not previously reported in
the literature, we showed that pVHL is dispensable for the normal
functions of terminally differentiated islet a-cells and b-cells in the
endocrine pancreas. Whereas mice with Vhl deletion in endocrine
pancreas showed normal survival, mice lacking pVHL in
pancreatic progenitor cells that give arise to both exocrine and
endocrine pancreas (Pdx1-Cre;Vhl f/f), exhibited significant
postnatal death. Most significantly, the few surviving Pdx1-
Cre;Vhl f/f mice developed MCA and islet hyperplasia, similar
to those found in VHL patients. Taken together, these results
provided evidence suggesting that pVHL is functionally important
for postnatal exocrine pancreas, and that VHL-associated
pancreatic lesions originate from progenitor cell lineages. The
novel model systems reported here will provide the basis for
further genetic studies to define molecular events involved in
VHL-associated pancreatic diseases.
Results
Loss of pVHL in a-cells is Dispensable and Insufficient to
Induce Tumorigenesis
VHL-associated pancreatic neuroendocrine tumors (PNET)
afflict 12–17% of VHL patients, and these tumors have been
demonstrated to exhibit focal positivity for glucagon [33]. Thus,
we speculated that these PNET might originate from glucagon-
positive a-cells deficient of pVHL in the endocrine pancreas. To
inactivate Vhl specifically in a-cells, we first generated an a-cell
specific Cre transgenic line (Glu-Cre) utilizing a rat glucagon
promoter sequence to direct Cre recombinase expression. By
crossing a Glu-Cre transgenic line with the Z/AP reporter mice
[34], we confirmed a-cell specific expression of Cre recombinase
in Glu-Cre;Z/AP pancreas at 5 and 12 months of age. As
expected, expression of Cre-recombinase localized in a-cells at the
outer ring of endocrine islets, as indicated by purple alkaline
phosphatase (AP) staining (Figure 1A, right panels). No positive AP
expression in pancreas was observed in age-matched control
genotypes of Glu-Cre and Z/AP mice (data not shown).
To determine the functional significance of Vhl in a-cells, the
Glu-Cre transgenic mice were next bred with mice in which exons
2 and 3 of the Vhl alleles are flanked by loxP sites (flox or f) [25].
Since variability in phenotype was documented in other tissue-
specific knockouts of Vhl [24,25], we generated Vhl-deficient a-cells
in A/J and C57BL/6 backgrounds. At the time of weaning (3–4
weeks after birth), we obtained the expected Mendelian frequen-
cies for all genotypes in both background strains (Table 1). Mouse
pancreases with Vhl deletion in a-cells (Glu-Cre;Vhl f/f, n=12)
appeared histological normal when compared to age-matched
control genotypes (Glu-Cre, n=8 and Vhl f/f, n=6) from 10
months to 23 months of age (data not shown). No obvious
physiological and behavioral phenotypes were observed for Glu-
Cre;Vhl f/f mice. To confirm that Vhl alleles were indeed deleted
in Glu-Cre;Vhl f/f mice, we isolated a-cells, b-cells and
endothelial cells from pancreatic islets via flow cytometry, and
obtained genomic DNA for each cell population. Genotyping
PCR analysis showed the expected deletion of Vhl alleles only in
glucagon-positive a-cells, but not in insulin-positive b-cells and
lectin-positive endothelial cells in Glu-Cre;Vhl f/f animals at 27
months of age (Figure 1B). Together, these results demonstrated
that Vhl is not essential for mature a-cells, and that deficiency of
Vhl in a-cells is insufficient to cause tumorigenesis in the endocrine
pancreas.
Vhl is not essential for Normal Function of Differentiated
Islet b-cell
Since b-cells are the major cell type in the endocrine pancreas
and some VHL PNETs are positive for insulin staining [33], we
next hypothesized that Vhl deficiency in insulin-positive b-cells
might lead to PNET development. To conditionally inactivate Vhl
in b-cells, we crossed Rip-Cre transgenic mice [35] with mice in
which exons 2 and 3 of the Vhl alleles are flanked by loxP sites (flox
or f). Similar to our findings in the Glu-Cre;Vhl colony, mice from
the Rip-Cre;Vhl colony were generated at the expected Mendelian
frequencies for all genotypes regardless of the strain backgrounds
(Table 2). Histological analysis of Rip-Cre;Vhl f/f mouse
pancreases (n=4) did not show any abnormality or islet tumor
formation when compared to age-matched control genotypes
(Rip-Cre and Vhl f/f) at 15 months of age (Figure S1A). Immuno-
staining of endocrine markers, such as insulin and glucagon, did
not reveal distinct features unique to mice deficient for pVHL in b-
cells (data not shown). Determination of Vhl allele status in the
Rip-Cre;Vhl f/f pancreas utilizing DNA isolated from microdis-
section further confirmed that Vhl deletion only occurred in the
expected endocrine islets, but not in the surrounding exocrine
pancreas (Figure S1B).
Notably, the physical appearance of the Rip-Cre;Vhl f/f mice
were proportionally smaller than their littermates at time of
weaning. Indeed, data confirmed that Rip-Cre;Vhl f/f mice
weighed significantly less than age-matched littermates at all time
points analyzed (Figure 2A). Since Vhl has been shown to regulate
glucose metabolism [36], we next measured fasting glucose levels
in a cohort of Rip-Cre;Vhl mice to determine if an elevated basal
glucose level was responsible for the small size seen in these mice.
Pancreatic Mouse Model of VHL
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glucose levels between control genotypes and Rip-Cre;Vhl f/f
mice at all time points measured (Figure 2B). We then speculated
that low expression of Cre-recombinase in the hypothalamus
reported for Rip-Cre transgenic mice [35] affects hormone
feedback loops regulated by the hypothalamus due to inactivation
of Vhl. Among various hormones regulated by the hypothalamus,
we chose to measure growth hormone since its deficiency is
associated with lean body mass. Again, our data did not show
significant differences in serum growth hormone levels between
control genotypes and Rip-Cre;Vhl f/f mice at all time points
tested (Figure 2C). Therefore, it is unclear if the small size of Rip-
Cre;Vhl f/f mice is due to the loss of Vhl in pancreatic islet b-cells
or in the hypothalamus.
Vhl is Functionally Important for Postnatal Exocrine
Pancreas
The most common manifestations of pancreatic VHL disease
are benign cysts and microcystic adenoma, which occur in 35–
75% of VHL patients [29,30]; however, it remains unclear
whether these lesions arise from the endocrine or exocrine
pancreas. To investigate whether loss of Vhl in the exocrine
pancreas can lead to cyst development, we utilized pancreatic and
duodenal homeobox 1 (Pdx1) transgenic mice in which cre
recombinase expression was driven by the Pdx1 promoter [37]. By
breeding Pdx1-Cre transgenic mice with Vhl floxed mice, we
generated mice with Vhl deletion in pancreatic endocrine and
exocrine cells as a result of Pdx1-Cre expression in pancreatic
progenitor cells during embryogenesis [37]. In contrast to mice
deficient in Vhl in a-cells or b-cells, we observed some lethality in
Pdx1-Cre;Vhl f/f mice. At the time of weaning, the distribution of
genotypes was significantly different from the expected values with
fewer than expected Pdx1-Cre;Vhl f/f mice in all three different
genetic backgrounds (Table 3). Statistically, observed lethality is
more severe in the A/J and Balb/C genetic backgrounds than in
the C57BL/6 background.
To determine if the lethality in Pdx1-Cre;Vhl f/f mice occurs
embryonically or postnatally, Mendelian ratios of the six possible
genotypes were observed immediately after birth and during
different postnatal time intervals (Table 4). The Pdx1-Cre;Vhl f/f
mice were born at the anticipated Mendelian ratio; however, these
mice could not survive more than 5 days postnatally (P5). We
further analyzed whole-mount histology of mouse pups (P1–P5) in
an attempt to uncover the cause of death. However, pathologists
blinded for genotypes could not distinguish Pdx1-Cre;Vhl f/f pups
from pups of control genotypes (Figure 3A). To confirm that the
Vhl alleles were indeed deleted in the pancreas of Pdx1-Cre;Vhl f/f
newborn pups, whole pup body DNA and pancreatic DNA were
isolated by laser capture microdissection. Genotyping analysis
demonstrated the expected Vhl deleted allele in the Pdx1-Cre;Vhl
f/f pup pancreas, as well as the floxed Vhl allele in cells of non-
pancreatic lineage, such as epithelial and endothelial cells
(Figure 3B, animal #3). Thus, whereas mice with homozygous
inactivation of Vhl in a-cells or b- cells (Glu-Cre;Vhl f/f and Rip-
Cre;Vhl f/f, respectively) showed normal survival rates, Pdx1-
Cre;Vhl f/f mice exhibited reduced postnatal survival that is likely
to be associated with exocrine dysfunction due to the loss of Vhl in
the exocrine pancreas.
Loss of Vhl in Exocrine Pancreas Recapitulates Cysts and
Microcystic Adenoma (MCA) That Develop in VHL
Patients
Since the postnatal lethality observed for Pdx1-Cre;Vhl f/f did
not exhibit 100% penetrance, we were able to perform histological
analysis of the pancreases of the few surviving Pdx1-Cre;Vhl f/f at
adulthood in the C57BL/6 background. At 6–7 months of age,
Pdx1-Cre;Vhl f/f mouse pancreases (n=2) were indistinguishable
Figure 1. Analysis of Glu-Cre;Vhl colony. A. Validation of the Glu-
Cre transgenic line with Z/AP reporter mice. H&E (panels a, c, e) and
alkaline phosphatase (AP; panels b, d, f) staining of a representative Glu-
Cre;Z/AP pancreas at 5 months of age. Expression of Glu-Cre localized in
a-cells at the outer ring of endocrine islets, as indicated by purple AP
stain. Pancreatic islets (Is) are as indicated in panel a, and images are
shown at 1006(a, b) and 4006(c, d, e, f) magnification. B. Genotyping
PCR using genomic DNA isolated from different cell populations of the
endocrine pancreas in Glu-Cre;Vhl f/f and Vhl f/f mice at 27 months of
age. Insulin-positive b-cells (I), glucagon-positive a-cells (G), and lectin-
positive endothelial cells (L) were collected via flow cytometry. Negative
(neg.) and positive (pos.) controls are shown next to the ladder (far left
lane). Top panel shows the PCR for b-globin alleles to demonstrate the
presence of genomic DNA for each cell population. Bottom panel
indicates the presence of deleted Vhl alleles only in a-cells of Glu-
Cre;Vhl f/f pancreas.
doi:10.1371/journal.pone.0004897.g001
Pancreatic Mouse Model of VHL
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months of age, an obvious loss of exocrine pancreas and fat
replacement were observed in Pdx1-Cre;Vhl f/f mice (n=3,
Figure 4A). Pathologists blinded for mouse genotypes further
identified the presence of cysts and MCA in all Pdx1-Cre;Vhl f/f
mice lacking pVHL in the pancreas (Figure 4A, panel c and f).
In VHL patients, the pancreatic cysts and MCA are highly
vascularized and characterized by a layer of epithelial lining
intermixed with endothelial cells forming capillaries around the
cysts [38]. To investigate the similarity between the MCA
developed in Pdx1-Cre;Vhl f/f pancreas and that found in VHL
patients, we used a CD31 antibody to identify endothelial cells,
and a cocktail of cytokeratin antibodies (MAK6) to identify the
epithelial cell lining of MCA. Immuno-histochemical staining
revealed that epithelial lining of the MCA was positive for MAK6
but not CD31, and that CD31 positive endothelial cells were
intermixed within MCA (Figure 4B). The extensive vasculature
network of MCA was more evident in Pdx1-Cre;Vhl f/f mice
injected with FITC-lectin prior to euthanizing (Figure 4C, panels a
and b). Utilizing immuno-fluorescent staining, we further
demonstrated that cytokeratin-positive epithelial lining and
lectin-positive vasculature did not co-localize, but instead were
distinctive cellular structures displayed by MCA in Pdx1-Cre;Vhl
f/f animals (Figure 4C, panels c and d).
Within the pancreas tissue largely replaced by fat deposition,
some islets in Pdx1-Cre;Vhl f/f animals appeared small and
abnormally shaped without much exocrine acinar cells surround-
ing them (Figure 4A, panel f), whereas some appeared hyperplastic
(Figure 5A). Regardless of the size, islets of Pdx1-Cre;Vhl f/f were
characterized by disorganized, dilated and tortuous vascular
networks within, as well as outside the islets (Figure 5B). Since
VHL neuroendocrine tumors are highly vascularized, it is possible
that these islets lacking pVHL might be progressing toward
developing pancreatic neuroendocrine tumors.
Modest Upregulation of Hif1a is Associated with
Pancreatic Phenotypes Developed in Pdx1-Cre;Vhl f/f
Mice
pVHL deficiency is known to result in constitutive HIF a-
subunits stabilization and increased expression of HIF target genes
[11]. To examine if the pancreatic phenotypes observed in Pdx1-
Cre;Vhl f/f mice were associated with activation of Hif1a or Hif2a
pathways, quantitative real-time PCR analysis was performed to
detect Hif1a and Hif2a mRNA expression. As shown in Figure 6A,
Table 1. Expected Mendelian distribution in Glu-Cre;Vhl colony.
Glu-Cre positive offspring
strain Cre;Vhl +/+ Cre;Vhl f/+ Cre;Vhl f/f N x
2 p-value
A/J 30.6% 46.9% 22.4% 49 0.837 0.658
C57BL/6 29.1% 40.5% 30.4% 79 2.873 0.238
Mendelian % 25.0% 50.0% 25.0%
Glu-Cre negative offspring
strain Vhl +/+ Vhl f/+ Vhl f/f N x
2 p-value
A/J 23.1% 30.8% 46.2% 13 3.308 0.191
C57BL/6 28.6% 53.6% 17.9% 28 0.786 0.675
Mendelian % 25.0% 50.0% 25.0%
Glu-Cre;Vhl f/+ mice were intercrossed and the genotypes of their offspring determined for each background strain at time of weaning.
doi:10.1371/journal.pone.0004897.t001
Table 2. Expected Mendelian distribution in Rip-Cre;Vhl colony.
Rip-Cre positive offspring
strain Cre;Vhl +/+ Cre;Vhl f/+ Cre;Vhl f/f N x
2 p-value
A/J 29.3% 56.0% 14.7% 75 4.307 0.116
C57BL/6 28.9% 53.9% 17.1% 76 2.605 0.272
Balb/C 30.4% 53.6% 16.1% 56 2.571 0.276
Mendelian % 25.0% 50.0% 25.0%
Rip-Cre negative offspring
strain Vhl +/+ Vhl f/+ Vhl f/f N x
2 p-value
A/J 34.2% 50.0% 15.8% 38 2.579 0.275
C57BL/6 29.4% 41.2% 29.4% 17 0.529 0.767
Balb/C 30.3% 57.6% 12.1% 33 2.939 0.230
Mendelian % 25.0% 50.0% 25.0%
Rip-Cre;Vhl f/+ mice were intercrossed and the genotypes of their offspring determined for each background strain at time of weaning.
doi:10.1371/journal.pone.0004897.t002
Pancreatic Mouse Model of VHL
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(n=3) when compared with control mice (n=3). Expression of
Hif2a and a Hif2a-preferred target gene (Vegf) [39] appeared
similar between control and Pdx1-Cre;Vhl f/f mice (Figure 6A,
data not shown). While the upregulation of Hif1a mRNA in Pdx1-
Cre;Vhl f/f pancreas was not statistically significant, we speculated
that this might be the reason why a few of the Pdx1-Cre;Vhl f/f
mice survived postnatal lethality. Consistent with the mRNA data,
we further confirmed the trend that protein expression of Hif1a
was upregulated in the pancreas of pVHL deficient mice utilizing a
Hif1a ELISA assay (Figure 6B).
Discussion
The major significance of this study is that generation of three
new pancreatic mouse models of VHL has allowed us to address
the cellular origins and biological roles of VHL during pancreatic
development and tumorigenesis. In terms of VHL’s role during
pancreatic development, we demonstrated that deletion of Vhl in
endocrine a-cells and b-cells which terminally differentiated
around E12.5 [40], does not appear to affect normal functions
of endocrine pancreas during embryogenesis, postnatal develop-
ment, and in adulthood (Glu-Cre;Vhl f/f and Rip-Cre;Vhl f/f
Figure 2. Physiological analyses of control and Rip-Cre;Vhl f/f mice. A. Body weight, B. Fasted glucose levels, and C. Serum growth
hormone levels of mice in the Rip-Cre;Vhl colony. Genotypes are as indicated and numbers of animals analyzed at each time point are shown in
tables. Data from three different strain backgrounds are combined and shown graphically.
doi:10.1371/journal.pone.0004897.g002
Pancreatic Mouse Model of VHL
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that give arise to ductal, exocrine and endocrine pancreas resulted
in significant postnatal death in mice (Pdx1-Cre;Vhl f/f animals),
even though pancreatic organogenesis was not affected during
embryonic development. Together, this data suggest that VHL is
functionally important in postnatal ductal and exocrine pancreas,
and that pVHL is not essential for mature endocrine pancreatic
cells. While this finding uncovers the novel aspect of VHL in
postnatal ductal and exocrine pancreas, it remains to be
determined whether HIF-dependent or HIF-independent path-
ways are involved.
In terms of VHL’s role during pancreatic tumorigenesis, little is
known about the cellular origins and molecular mechanisms
related to VHL-associated pancreatic diseases, even though a large
portion of VHL patients are affected by pancreatic manifestations,
such as cysts, MCA and neuroendocrine tumors. By specifically
inactivating Vhl in distinct pancreatic cell populations, we reported
the first mouse model of VHL that recapitulates some of the
clinical features found in the pancreas of VHL patients, and
demonstrated that inactivation of Vhl in the endocrine pancreas is
insufficient to initiate tumorigenesis. VHL-associated pancreatic
lesions were only found in mice where Vhl was inactivated in
pancreatic progenitor cells (Pdx1-Cre;Vhl f/f mice), but not in
mice in which Vhl was inactivated in mature endocrine cells (Glu-
Cre;Vhl f/f and Rip-Cre;Vhl f/f mice). Thus, our data supports
the notion of a progenitor cell origin for these VHL-associated
pancreatic lesions. In addition, it has been previously suggested by
histopathological studies that MCA originated from pancreatic
exocrine cells, such as the centroacinar cells [41,42] or ductal cells
[43,44]. Moreover, none of the VHL patients (n.108) with PNET
disease evaluated at our center had a functional neoplasm by
hormone levels or symptoms [45]. Together, these data suggest
that VHL-associated MCA and PNET originate from pancreatic
ductal or exocrine progenitor cells, not differentiated endocrine
cells. Analogous to our hypothesis, VHL-associated hemangio-
blastomas have been demonstrated to derive from embryologic
multipotent cells [46]. However, further studies will be required to
definitively determine if these VHL-associated pancreatic mani-
festations can be recapitulated when Vhl is specifically deleted in
progenitor cells of ductal, exocrine or endocrine lineage.
Similar to pervious reports on Vhl knockout mice [24,25], we
also observed variability in phenotypic penetrance of the Vhl
deletion due to differences in mouse genetic backgrounds. The
postnatal lethality in Pdx1-Cre;Vhl f/f mice was most severe in A/
J and Balb/C background strains, but not as severe in the C57BL/
6 background strain. This finding suggests that strain-specific
genetic modifiers may provide protection for the survival of these
mice with pVHL deficiency in the pancreas. Notably, we showed
that pancreatic phenotypes observed in Pdx1-Cre;Vhl f/f mice
correlate with a modest upregulation of Hif1a, but not HIf2a.I ti s
thus possible that these strain-specific genetic modifiers may
function to interfere with VHL downstream signaling, and
compensate for the loss of pVHL. This does not exclude the
possibility that the pancreatic phenotypes observed in Pdx1-
Cre;Vhl f/f mice resulted from mechanisms completely indepen-
dent of HIF signaling pathways, such as VHL’s role in regulating
extracellular matrix assembly [47]. Identification of these modifier
genes and further comparative functional analysis utilizing mice
deficient in Hif1a and Hif2a will provide insight into the precise
molecular mechanisms leading to the development of VHL-
associated pancreatic disease.
An unexpected observation during our studies was the small size
seen in mice deficient in pVHL in the islet b-cells. While our
analyses excluded the idea that alterations in growth hormone and
basal glucose levels led to this phenotype in Rip-Cre;Vhl f/f mice, it
is described in the literature that pVHL regulates glucose
metabolism in liver and kidney cells [10,36]. Establishment of our
Rip-Cre;Vhl f/f homozygous mice now allows us to begin
investigating whether or not pVHL also plays an important role
in glucose sensing in pancreatic islet b-cells, such as via glucose
transporter 1 (Glut1). However, phenotypes seen in Rip-Cre;Vhl f/f
mice are confounded by the fact that Rip-Cre is expressed at a low
level in the hypothalamus [35]. Thus, it would be critical to confirm
and determine that deletion of Vhl indeed occurred in particular
nuclei within the hypothalamus in Rip-Cre;Vhl f/f homozygous
mice. Only when that information is available, will we be able to
conclusively interpret the physiological data resulting from the loss
of pVHL in pancreatic islet b-cells or in the hypothalamus.
In summary, to decipher the functional significance of pVHL in
the pancreas during development and tumorigenesis, we condi-
tionally inactivated Vhl in distinct pancreatic cell populations and
reported the first mouse model of VHL that recapitulates clinical
features found in the pancreas of VHL patients. Importantly, our
data demonstrated that pVHL is functionally important for
Table 3. Lethality in generating Pdx1-Cre;Vhl f/f in A/J and Balb/C backgrounds.
Pdx1-Cre positive offspring
strain Cre;Vhl +/+ Cre;Vhl f/+ Cre;Vhl f/f N x
2 p-value
A/J 18.6% 76.7% 4.7% 43 13.977 0.001
C57BL/6 37.3% 47.5% 15.3% 59 5.881 0.053
Balb/C 31.5% 64.8% 3.7% 54 13.074 0.001
Mendelian % 25.0% 50.0% 25.0%
Pdx1-Cre negative offspring
strain Vhl +/+ Vhl f/+ Vhl f/f N x
2 p-value
A/J 33.3% 45.8% 20.8% 24 0.917 0.632
C57BL/6 22.2% 55.6% 22.2% 18 0.222 0.895
Balb/C 22.7% 50.0% 27.3% 22 0.091 0.956
Mendelian % 25.0% 50.0% 25.0%
Pdx1-Cre;Vhl f/+ mice were intercrossed and the genotypes of their offspring determined for each background strain at time of weaning.
doi:10.1371/journal.pone.0004897.t003
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pancreatic progenitor cells, not mature endocrine cells, as the cell
of origin for VHL-associated pancreatic lesions. The novel mouse
model systems reported in this study will provide the foundation
for further functional and genetic analysis to advance our
understanding of VHL-associated pancreatic manifestations.
Materials and Methods
Ethics Statement
National Cancer Institute (NCI) and NCI-Frederick are
accredited by AAALAC International and follows the Public
Health Service Policy for the Care and Use of Laboratory
Animals. Animal care was provided in accordance with the
procedures outlined in the ‘‘Guide for Care and Use of Laboratory
Animals (National Research Council; 1996; National Academy
Press; Washington DC). All animal experiments were conducted in
accordance with NIH-approved protocols and guidelines.
Animals and Genotyping
Mice carrying the Vhl alleles flanked by loxP sites [25] were re-
derived in C57BL/6, A/J and Balb/C backgrounds before
crossing with different Cre transgenic mice. The Pdx1-Cre
Figure 3. Histological and molecular analyses of control and Pdx1-Cre;Vhl f/f pup pancreas. A. H&E staining of representative Pdx1-Cre,
Vhl f/f (panels a and c) and control Pdx1-Cre (panels b and d) mouse pups at postnatal day 3 (P3). Magnified (506) pup pancreas are shown (panels c
and d), and islets are indicated by arrows. B. PCR analysis of Vhl allele status. DNA isolated from whole pup section (whole body DNA) and from
pancreas via laser capture microdissection (LCM pancreas DNA) was used to detect Vhl allele status (floxed, wildtype-wt, deleted). Genotyping PCR
was performed in duplicate for each pup (#1–#4). PCR results for Pdx1-Cre;Vhl f/f (#3)and Pdx1-Cre (#4) are the same mouse pups shown in A.
doi:10.1371/journal.pone.0004897.g003
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Rip-Cre (B6.Cg-Tg (Ins2-cre)25Mgn/J) transgenic mice were
purchased from The Jackson Laboratory (stock number:
003573). The Glu-Cre transgenic mice were generated utilizing
the pBKCMV/Glu-CreGH plasmid kindly provided by Dr. M.
Magnuson. Briefly, the plasmid fragment containing 2.3 kb of rat
glucagon promoter upstream of the Cre-recombinase was isolated
by SalI and NotI digestion prior to injection to generate transgenic
founder lines. Tissue expression of Glu-Cre was evaluated in
offspring from crosses of the Glu-Cre transgenic mice with Z/AP
reporter mice [34]. Detailed analysis of the Glu-Cre transgenic
mice will be described elsewhere. Cre recombinase expression in
tissues of Z/AP mice will delete the floxed LacZ expression cassette
upstream of the hPLAP gene, allowing hPLAP expression and
detection by standard staining techniques. Tissue sections were
counterstained with nuclear fast red (Sigma, St. Louis, MO).
All mice were genotyped by PCR using DNA isolated from tail
snips. Tails were digested overnight in 150 ml of DirectPCR Lysis
buffer (Viagen Biotech, Los Angeles, CA) following manufacturer’s
protocol, and used directly for PCR. Cells collected from laser
capture microdissection (LCM) and flow cytometry were digested
overnight in buffer (100 mM Tris-Cl pH8.0, 50 mM EDTA, 0.2%
SDS, 200 mM NaCl) containing fresh proteinase K (1 mg/ml).
Genomic DNA was isolated following a standard salt and ethanol
precipitation protocol. DNA concentration was determined using
NanoDrop ND-1000 (NanoDrop, Wilmington, DE), and equal
amounts of DNA were used for PCR analysis. The annealing
temperature for Pdx1-Cre, Glu-Cre, and b-globin was 55uC.
Primers for Pdx1-Cre (forward: 59-TTGAAACAAGTG-
CAGGTGTTCG; reverse: 59-CCTGAAGATATAGAAGA-
TAATCG), and for Glu-Cre (forward: 59-AAAATGCAGGCA-
GATGAGCA; reverse: 59-CAGGCTGTTGGCGAAGACA),
and for b-globin (forward: 59-CCAATCTGCTCACACAGGA-
TAGAGAGGGCAGG; reverse: 59-CCTTGAGGCTGTC-
CAAGTGATTCAGGCCATCG) were utilized to generate
500 bp, 401 bp, and 494 bp PCR products, respectively. The
PCR conditions for detecting floxed and deleted Vhl alleles have
been described [48].
Animal Tissue Collection and Processing
The pancreatic tissue was processed for frozen histological
analysisbyembedding tissuesinTissue-TekOCTfreezingmedium,
and for formalin-fixed paraffin embedding (FFPE). Frozen (10–
20 mm) and FFPE pancreas sections (5 mm) were routinely stained
with Mayer’s hematoxylin and eosin (H&E) for histopathological
analysis. For all histological analysis, Cre;Vhl f/f mice were
compared with age-matched controls genotypes of Cre, Vhl f/f,
Vhl f/+ and Cre;Vhl f/+ mice. Only representative control
genotypes are shown in figures. For whole mount mouse pup
analysis, a sagittal incision was made to allow formalin fixation to
penetrate internal organs. Mouse pups were divided into two parts
via the sagittal incision prior to the paraffin embedding process.
FITC-lectin perfusion to visualize the blood vasculature was
performed as described [49]. Briefly mice were injected intrave-
nously via tail vein with 50 ug of FITC-labeled lectin (Lycopersicon
esculentum, Vector Laboratories, Burlingame, CA), which was
allowed to circulate for 3 minutes. Then mice were euthanized via
cervical dislocation, and the pancreas was removed. All procedures
involving mice were performed with approval by the NIH
Institutional Animal Care and Use Committee.
Islet Isolation, Dissociation, and Flow Cytometry
Mice were perfused with FITC-lectin as described above prior to
being euthanized. Pancreatic islets were isolated by standard
techniques, with minor adaptations. Briefly, pancreata were inflated
viabileduct cannulation andretrograde pancreatic duct injectionof
3–4 ml of ice-cold collagenase type XI (1 mg/ml in HBSS, Sigma,
St. Louis, MO). Following digestion (37uC, 14 min), pancreata were
dispersed by gently aspirating through a 14G needle, then filtered
through a metal strainer (0.8 mm). Pancreas suspensions were then
subjected to buoyant density gradient centrifugation (14–15%
Optiprep, Accurate Chemicals, Westbury, NY), followed by
handpicking with great care to collect all visible islets.
Isolated islets were dissociated into single cell suspensions by
careful pipeting after washing in 2 mM EDTA/PBS, and
incubation for 10 min at room temperature in Ca
2+ free phosphate
buffered saline (PBS) supplemented with 0.025% trypsin. Disso-
ciated islet cells were immediately fixed and permeabilized in 4%
paraformaldehyde (PFA) (Electron Microscopy Sciences, Hatfield,
PA), 0.1% saponin, (Fluka Chemicals, Switzerland) in PBS for 30
min at room temperature. After removing PFA by washing in 0.1
saponin/1% bovine serum albumin (BSA)/PBS, islet cells were
stained intracytoplasmically for 30 min with antibodies against
insulin (1:300, guinea pig, DAKO, Carpinteria, CA). After
Table 4. Postnatal death in Pdx1-Cre;Vhl f/f mice.
Pdx1-Cre positive offspring
Postnatal (P) days Cre;Vhl +/+ Cre;Vhl f/+ Cre;Vhl f/f N x
2 p-value
P1 (birth) 5.3% 63.2% 31.6% 19 3.947 0.139
P3–P5 22.6% 38.7% 38.7% 31 3.194 0.203
P7–P10 31.3% 68.8% 0.0% 16 5.375 0.068
P21 (weaning) 25.8% 70.1% 4.1% 97 24.77 4.2E-06
Pdx1-Cre negative offspring
Postnatal (P) days Vhl +/+ Vhl f/+ Vhl f/f N x
2 p-value
P1 (birth) 12.5% 50.0% 37.5% 8 1.000 0.607
P3–P5 14.3% 57.1% 28.6% 7 0.429 0.807
P7–P10 60.0% 40.0% 0.0% 10 7.600 0.022
P21 (weaning) 28.3% 47.8% 23.9% 46 0.261 0.878
Table 4 combines data from A/J and Balb/C background strains and genotypes were determined at different postnatal (P) time points.
doi:10.1371/journal.pone.0004897.t004
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glucagon monoclonal antibody (clone K79bB10, Sigma, St. Louis,
MO) using Zenon (pre)labeling technology for mouse IgG1 (Pacific
Blue, Invitrogen, Carlsbad, CA), and an highly cross-absorbed,
second-step polyclonal antibodies (pAb), anti-guinea pig-Cy5
(Jackson ImmunoResearch, West Grove, PA). After the final wash
in 1%BSA/saponin, cells were post-fixed in 1% PFA, and
concomitantly 4-way sorted for insulin positive, glucagon positive,
FITC-lectin positive and unstained samples using a FACSAria cell
sorter with Diva software (BD Biosciences, San Jose, CA).
Electronic gating was set to include viable cells on the basis of
forward scatter versus side scatter while the doublet-exclusion
gating setup was applied to eliminate non-dissociated islet cell
couplets on the basis of pulse width versus total signal area (linear
scale). Sorted islet cell subsets were washed in PBS and kept frozen
at 270uC until DNA extraction.
Figure 4. Histological analysis of the microcystic adenomas (MCA) which developed in Pdx1-Cre;Vhl f/f adult pancreas. A. H&E
staining of pancreas from representative control Pdx1-Cre (panel a), and Vhl f/+ (panel d), and two different Pdx1-Cre;Vhl f/f (panels b, c, e and f) mice
at 16–18 months of age. Gross pancreas histology is shown at 406in panels a, b, d, e., and areas (black boxes) in panels b and e are magnified at
2006in panels c and f. Islets are indicated by arrows and MCA are indicated by asterisk. B. Immuno-histochemical staining of MCA utilizing a CD31
antibody (top panel) and a pan-keratin MAK6 antibody (bottom panel) to identify endothelial cells and epithelial cells of MCA, respectively. Arrows
indicate CD31 positive endothelial cells. Images shown are at 5006magnification. C. Representative immuno-fluorescent images of MCA, indicated
by asterisks. FITC-lectin identifies endothelial cells, DAPI identifies cell nuclei and cytokeratin 18 identifies epithelial cells within MCA. Top panels are
at 2006and bottom panels are at 4006magnification.
doi:10.1371/journal.pone.0004897.g004
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Whole bloodwascollectedvia orbitalormandiblebleed to isolate
serum. Growth hormone levels were measured withthe Mouse/Rat
Growth Hormone ELISA (Diagnostic Systems Labroatories, Inc.,
Webster, TX) according to the manufacturer’s instructions.
Glucose Measurements
Mice underwent a 24 hour fast prior to collecting whole blood
via a tail snip. Blood glucose was measured using a glucometer
(Ascensia Contour, Bayer HealthCare, Mishawaka, IN).
Immuno-Staining for Histological Analysis
For immuno-histochemical staining, monoclonal mouse anti-
human CD31 (1:25, DAKO clone JC70A, Carpinteria, CA)
antibodies, and a cocktail of mouse-anti-cytokeratin, or MAK6
antibodies (predilute, Invitrogen, Carlsbad, CA) were used. The
Universal DakoCytomation Labelled Streptavidin-Biotin2 System,
Horseradish Peroxidase (LSAB2 System, HRP) followed by the
additiona of DAB chromogen was utilized for antigen detection.
Sections were counterstained in Mayer’s hematoxylin, mounted
and photographed using a Zeiss microscope.
Figure 5. Histological analysis of the endocrine pancreas in Pdx1-Cre;Vhl f/f mice. A. Immuno-fluorescent staining of representative
pancreas in Pdx1-Cre (panel a) and Pdx1-Cre;Vhl f/f mice (panels b and c) to demonstrate the abnormally shaped and hyperplastic islets (red) in Pdx1-
Cre;Vhl f/f mice at 16–18 months of age. Images are taken at 1006. B. Immuno-fluorescent images of representative pancreas in Pdx1-Cre (panels a–
c) and Pdx1-Cre;Vhl f/f (panels d–i) to demonstrate hypervascularity within islets of Pdx1-Cre;Vhl f/f mice. Blood vessels are visualized via FITC-lectin
injection (green; panels b, e, and h) while pancreatic islets are identified using an anti-insulin antibody (red; panels c, f, and i). Images are taken at
2006.
doi:10.1371/journal.pone.0004897.g005
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sections were briefly fixed in 4% paraformaldehyde, washed in PBS,
and incubated inblocking buffer(5% normal goat serum/2.5% BSA
in PBS). Primary antibodies guinea pig anti-swine insulin (1:500,
DAKO, Carpinteria, CA) and rabbit anti-cytokeratin 18 (1:50,
Santa Cruz Biotechnology, Santa Cruz, CA) were diluted in 0.56
blocking buffer. Sections were incubated with primary antibody
overnight at 4uC in a humidified chamber followed by brief washes
in PBS. Secondary antibodies Alexa Fluor 594 or 633-conjugated
anti-guinea pig and Alexa Fluor 594 -conjugated anti-rabbit (1:200;
Invitrogen, Carlsbad, CA) were applied to sections. After incubation
at room temperature for one hour, the fluorescently stained sections
were washed several times in PBS, cover slipped using mounting
medium with DAPI (Vector Laboratories, Burlingame, CA), and
visualized using either a Zeiss Axiovert fluorescence microscope
(Carl Zeiss MicroImaging, Thornwood, NY).
RNA collection and Quantitative Real-Time PCR
Islet RNA was collected from frozen pancreas sections on slides
by microdissection and extracted using the PicoPure RNA
Isolation kit (Arcturus, Mountain View, CA). RNA concentration
was determined by NanoDrop ND-1000 (NanoDrop, Wilmington,
DE), and equal amounts (1.4 mg) of total RNA was used to
generate cDNA. Reverse transcription and quantitative PCR was
performed as described previously [50]. TaqMan primers and
probes were purchased from Applied Biosystems (Foster City, CA):
Gapdh (Mm99999915_g1), Hif1a (Mm00468878_m1), Hif2a/
Epas1 (Mm0438717_m1).
Hif1a ELISA
Total pancreatic protein lysate was harvested by sonicating
pancreas on ice in RIPA buffer (Pierce, Rockford, IL) containing
16 Complete Protease Inhibitor Cocktail (Roche, Nutley, NJ).
Protein concentration was determined with the Quick Start
Bradford Protein Assay (Bio-Rad Laboratories, Hercules, CA).
Mouse Hif1a protein was measured using Surveyor IC human/
mouse total Hif1a immunoassay according to manufacturer’s
protocols (R&D Systems, Minneapolis, MN).
Statistical Analysis
Statistical analysis was performed using GraphPad Prism v.5.01
and Microsoft Excel. The distributions of genotypes after inter-
breeding of Cre;Vhl f/+ mice were compared to the expected
Mendelian distributions with Chi-square-test. Chi-square and p-
value (2 degrees of freedom) are indicated for each strain and each
postnatal time point in Tables. Mouse body weight, serum growth
hormone levels, and fasted blood glucose levels were evaluated
with one-way ANOVA with multiple comparisons testing.
Expression data of Hif1a and Hif2a were analyzed with Mann-
Whitney (unpaired, nonparametric) t-test. A p value less than (,)
0.05 was considered statistically significant.
Supporting Information
Figure S1 A. H&E staining of representative Rip-Cre and Rip-
Cre;Vhl f/f pancreas at 15 months of age. Islets are as indicated
(Is), and images are taken at 1006. B. Genotyping PCR to
determine Vhl allele status using genomic DNA isolated from
Figure 6. Expression analysis in Pdx1-Cre;Vhl f/f pancreas. Relative gene expression of Hif1a and Hif2a mRNA transcripts (A) and protein
expression of Hif1a (B) in pancreas of control (Pdx1-Cre and Vhl f/+), and Pdx1-Cre;Vhl f/f genotypes at older than 16 months of age. Each column
represents the average expression of three mice for the indicated genotype.
doi:10.1371/journal.pone.0004897.g006
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and Rip-Cre mice at 12 months of age.
Found at: doi:10.1371/journal.pone.0004897.s001 (2.54 MB TIF)
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